Screener
Regeneron Pharmaceuticals REGN Reimbursement for manufacturing of commercial supplies — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| (In millions) | Statement of Operations Classification | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|---|
| Regeneron's share of profits | Collaboration revenue | $2,032.6 | $1,282.1 | $3,483.4 | $2,300.2 |
| Reimbursement for manufacturing of commercial supplies | Collaboration revenue | $141.7 | $161.5 | $296.0 | $326.6 |
| Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses | (R&D expense) | $(19.4) | $(18.0) | $(36.1) | $(33.5) |
| Reimbursement of commercialization-related expenses | Reduction of SG&A expense | $188.8 | $194.0 | $372.9 | $353.2 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue?
- Regeneron Pharmaceuticals (REGN) reported reimbursement for manufacturing of commercial supplies — revenue of $141.7M in Q2 2026.
- How has Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue changed year-over-year?
- Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue decreased by 12.3% year-over-year, from $161.5M to $141.7M.
- What is the long-term trend for Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue has grown at a 7.1% compound annual growth rate (CAGR), from $488.8M to $642.3M.
- What does reimbursement for manufacturing of commercial supplies — revenue mean?
- This metric represents revenue generated from providing contract manufacturing services for commercial-stage pharmaceutical products to collaboration partners. It reflects the recovery of costs and associated fees for producing drug supplies that are marketed by third parties or joint ventures. This stream highlights the company's role as a manufacturing partner within broader strategic alliances.
Ask your AI about Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude